{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T04:09:57Z","timestamp":1777522197669,"version":"3.51.4"},"reference-count":68,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["jpet.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1124\/jpet.119.262246","type":"journal-article","created":{"date-parts":[[2019,11,19]],"date-time":"2019-11-19T21:25:13Z","timestamp":1574198713000},"page":"157-165","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":38,"title":["3,4-Dihydroxyphenylacetaldehyde Is More Efficient than Dopamine in Oligomerizing and Quinonizing \u03b1-Synuclein"],"prefix":"10.1016","volume":"372","author":[{"given":"Yunden","family":"Jinsmaa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Risa","family":"Isonaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yehonatan","family":"Sharabi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David S.","family":"Goldstein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1124\/jpet.119.262246_bib1","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1021\/acs.chemrestox.5b00528","article-title":"Antioxidant-mediated modulation of protein reactivity for 3,4-dihydroxyphenylacetaldehyde, a toxic dopamine metabolite","volume":"29","author":"Anderson","year":"2016","journal-title":"Chem Res Toxicol"},{"key":"10.1124\/jpet.119.262246_bib2","doi-asserted-by":"crossref","first-page":"26978","DOI":"10.1074\/jbc.M111.249532","article-title":"Oxidation of 3,4-dihydroxyphenylacetaldehyde, a toxic dopaminergic metabolite, to a semiquinone radical and an ortho-quinone","volume":"286","author":"Anderson","year":"2011","journal-title":"J Biol Chem"},{"key":"10.1124\/jpet.119.262246_bib3","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/BF03033137","article-title":"Dopamine- or L-DOPA-induced neurotoxicity: the role of dopamine quinone formation and tyrosinase in a model of Parkinson\u2019s disease","volume":"5","author":"Asanuma","year":"2003","journal-title":"Neurotox Res"},{"key":"10.1124\/jpet.119.262246_bib4","doi-asserted-by":"crossref","first-page":"104514","DOI":"10.1016\/j.neuint.2019.104514","article-title":"5-S-cysteinyl-dopamine, a neurotoxic endogenous metabolite of dopamine: implications for Parkinson\u2019s disease","volume":"129","author":"Badillo-Ram\u00edrez","year":"2019","journal-title":"Neurochem Int"},{"key":"10.1124\/jpet.119.262246_bib5","first-page":"878935","article-title":"Dopamine cytotoxicity involves both oxidative and nonoxidative pathways in SH-SY5Y cells: potential role of alpha-synuclein overexpression and proteasomal inhibition in the etiopathogenesis of Parkinson\u2019s disease","volume":"2014","author":"Banerjee","year":"2014","journal-title":"Parkinsons Dis"},{"key":"10.1124\/jpet.119.262246_bib6","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/S0031-6997(25)06961-3","article-title":"Amine oxidase and amine metabolism","volume":"4","author":"Blaschko","year":"1952","journal-title":"Pharmacol Rev"},{"key":"10.1124\/jpet.119.262246_bib7","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1126\/science.aam9080","article-title":"Dopamine oxidation mediates mitochondrial and lysosomal dysfunction in Parkinson\u2019s disease","volume":"357","author":"Burbulla","year":"2017","journal-title":"Science"},{"key":"10.1124\/jpet.119.262246_bib8","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s00401-007-0303-9","article-title":"Aggregation of \u03b1-synuclein by DOPAL, the monoamine oxidase metabolite of dopamine","volume":"115","author":"Burke","year":"2008","journal-title":"Acta Neuropathol"},{"key":"10.1124\/jpet.119.262246_bib9","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/S0006-8993(03)03354-7","article-title":"3,4-Dihydroxyphenylacetaldehyde is the toxic dopamine metabolite in vivo: implications for Parkinson\u2019s disease pathogenesis","volume":"989","author":"Burke","year":"2003","journal-title":"Brain Res"},{"key":"10.1124\/jpet.119.262246_bib10","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.cotox.2018.12.002","article-title":"Biogenic aldehyde-mediated mechanisms of toxicity in neurodegenerative disease","volume":"13","author":"Cagle","year":"2019","journal-title":"Curr Opin Toxicol"},{"key":"10.1124\/jpet.119.262246_bib11","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1111\/j.1600-0404.1991.tb05014.x","article-title":"Possible mechanisms underlying the special vulnerability of dopaminergic neurons","volume":"136","author":"Carlsson","year":"1991","journal-title":"Acta Neurol Scand Suppl"},{"key":"10.1124\/jpet.119.262246_bib12","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1089\/ars.2015.6343","article-title":"Alpha-synuclein oligomers interact with metal ions to induce oxidative stress and neuronal death in Parkinson\u2019s disease","volume":"24","author":"Deas","year":"2016","journal-title":"Antioxid Redox Signal"},{"key":"10.1124\/jpet.119.262246_bib13","doi-asserted-by":"crossref","first-page":"11317","DOI":"10.1021\/acs.inorgchem.7b01757","article-title":"Prion peptides are extremely sensitive to copper induced oxidative stress","volume":"56","author":"Dell\u2019Acqua","year":"2017","journal-title":"Inorg Chem"},{"key":"10.1124\/jpet.119.262246_bib14","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S0163-7258(01)00144-9","article-title":"The role of neuronal and extraneuronal plasma membrane transporters in the inactivation of peripheral catecholamines","volume":"91","author":"Eisenhofer","year":"2001","journal-title":"Pharmacol Ther"},{"key":"10.1124\/jpet.119.262246_bib15","doi-asserted-by":"crossref","first-page":"27660","DOI":"10.1074\/jbc.M115.686584","article-title":"Oligomerization and membrane-binding properties of covalent adducts formed by the interaction of \u03b1-synuclein with the toxic dopamine metabolite 3,4-dihydroxyphenylacetaldehyde (DOPAL)","volume":"290","author":"Follmer","year":"2015","journal-title":"J Biol Chem"},{"key":"10.1124\/jpet.119.262246_bib16","doi-asserted-by":"crossref","first-page":"3320","DOI":"10.1172\/JCI45803","article-title":"Intra-neuronal vesicular uptake of catecholamines is decreased in patients with Lewy body diseases","volume":"121","author":"Goldstein","year":"2011","journal-title":"J Clin Invest"},{"key":"10.1124\/jpet.119.262246_bib17","doi-asserted-by":"crossref","first-page":"3289","DOI":"10.1007\/s11064-017-2371-0","article-title":"N-acetylcysteine prevents the increase in spontaneous oxidation of dopamine during monoamine oxidase inhibition in PC12 cells","volume":"42","author":"Goldstein","year":"2017","journal-title":"Neurochem Res"},{"key":"10.1124\/jpet.119.262246_bib18","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.pharmthera.2014.06.006","article-title":"Catecholamine autotoxicity. Implications for pharmacology and therapeutics of Parkinson disease and related disorders","volume":"144","author":"Goldstein","year":"2014","journal-title":"Pharmacol Ther"},{"key":"10.1124\/jpet.119.262246_bib19","doi-asserted-by":"crossref","first-page":"e130441","DOI":"10.1172\/jci.insight.130441","article-title":"Computational modeling reveals multiple abnormalities of myocardial noradrenergic function in Lewy body diseases","volume":"5","author":"Goldstein","year":"2019","journal-title":"JCI Insight"},{"key":"10.1124\/jpet.119.262246_bib20","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1111\/j.1468-1331.2010.03246.x","article-title":"Catechols in post-mortem brain of patients with Parkinson disease","volume":"18","author":"Goldstein","year":"2011","journal-title":"Eur J Neurol"},{"key":"10.1124\/jpet.119.262246_bib21","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/j.parkreldis.2015.03.006","article-title":"Decreased vesicular storage and aldehyde dehydrogenase activity in multiple system atrophy","volume":"21","author":"Goldstein","year":"2015","journal-title":"Parkinsonism Relat Disord"},{"key":"10.1124\/jpet.119.262246_bib22","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.parkreldis.2016.12.011","article-title":"Determinants of denervation-independent depletion of putamen dopamine in Parkinson\u2019s disease and multiple system atrophy","volume":"35","author":"Goldstein","year":"2017","journal-title":"Parkinsonism Relat Disord"},{"key":"10.1124\/jpet.119.262246_bib23","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1111\/jnc.12345","article-title":"Determinants of buildup of the toxic dopamine metabolite DOPAL in Parkinson\u2019s disease","volume":"126","author":"Goldstein","year":"2013","journal-title":"J Neurochem"},{"key":"10.1124\/jpet.119.262246_bib24","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1186\/s12974-017-1018-z","article-title":"Alpha-synuclein oligomer-selective antibodies reduce intracellular accumulation and mitochondrial impairment in alpha-synuclein exposed astrocytes","volume":"14","author":"Gustafsson","year":"2017","journal-title":"J Neuroinflammation"},{"key":"10.1124\/jpet.119.262246_bib25","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1016\/j.febslet.2006.03.018","article-title":"\u03b1-Synuclein facilitates the toxicity of oxidized catechol metabolites: implications for selective neurodegeneration in Parkinson\u2019s disease","volume":"580","author":"Hasegawa","year":"2006","journal-title":"FEBS Lett"},{"key":"10.1124\/jpet.119.262246_bib26","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1007\/s10863-009-9257-z","article-title":"The role of dopamine oxidation in mitochondrial dysfunction: implications for Parkinson\u2019s disease","volume":"41","author":"Hastings","year":"2009","journal-title":"J Bioenerg Biomembr"},{"key":"10.1124\/jpet.119.262246_bib27","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1021\/acschemneuro.7b00034","article-title":"Are dopamine oxidation metabolites involved in the loss of dopaminergic neurons in the nigrostriatal system in Parkinson\u2019s disease?","volume":"8","author":"Herrera","year":"2017","journal-title":"ACS Chem Neurosci"},{"key":"10.1124\/jpet.119.262246_bib28","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/S0031-6997(25)07154-6","article-title":"Dopamine (3-hydroxytyramine) and brain function","volume":"18","author":"Hornykiewicz","year":"1966","journal-title":"Pharmacol Rev"},{"key":"10.1124\/jpet.119.262246_bib29","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1007\/s12640-018-9969-0","article-title":"Novel alpha-synuclein oligomers formed with the aminochrome-glutathione conjugate are not neurotoxic","volume":"35","author":"Huenchuguala","year":"2019","journal-title":"Neurotox Res"},{"key":"10.1124\/jpet.119.262246_bib30","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/j.bbadis.2011.02.013","article-title":"Mitochondrial dysfunction mediated by quinone oxidation products of dopamine: implications in dopamine cytotoxicity and pathogenesis of Parkinson\u2019s disease","volume":"1812","author":"Jana","year":"2011","journal-title":"Biochim Biophys Acta"},{"key":"10.1124\/jpet.119.262246_bib31","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1124\/jpet.118.248492","article-title":"3,4-Dihydroxyphenylacetaldehyde-induced protein modifications and their mitigation by N-acetylcysteine","volume":"366","author":"Jinsmaa","year":"2018","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.119.262246_bib32","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.neulet.2014.03.016","article-title":"Divalent metal ions enhance DOPAL-induced oligomerization of alpha-synuclein","volume":"569","author":"Jinsmaa","year":"2014","journal-title":"Neurosci Lett"},{"key":"10.1124\/jpet.119.262246_bib33","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1126\/science.1147241","article-title":"Mussel-inspired surface chemistry for multifunctional coatings","volume":"318","author":"Lee","year":"2007","journal-title":"Science"},{"key":"10.1124\/jpet.119.262246_bib34","doi-asserted-by":"crossref","first-page":"216","DOI":"10.3858\/emm.2011.43.4.026","article-title":"Dopamine promotes formation and secretion of non-fibrillar alpha-synuclein oligomers","volume":"43","author":"Lee","year":"2011","journal-title":"Exp Mol Med"},{"key":"10.1124\/jpet.119.262246_bib35","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1007\/s11064-009-9986-8","article-title":"Modulation of \u03b1-synuclein aggregation by dopamine: a review","volume":"34","author":"Leong","year":"2009","journal-title":"Neurochem Res"},{"key":"10.1124\/jpet.119.262246_bib36","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1111\/j.1471-4159.2012.07756.x","article-title":"Dopaminochrome induces caspase-independent apoptosis in the mesencephalic cell line, MN9D","volume":"122","author":"Linsenbardt","year":"2012","journal-title":"J Neurochem"},{"key":"10.1124\/jpet.119.262246_bib37","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1016\/j.neuro.2009.07.006","article-title":"Cytotoxicity of dopaminochrome in the mesencephalic cell line, MN9D, is dependent upon oxidative stress","volume":"30","author":"Linsenbardt","year":"2009","journal-title":"Neurotoxicology"},{"key":"10.1124\/jpet.119.262246_bib38","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/1055-8330(95)90016-0","article-title":"An endogenous dopaminergic neurotoxin: implication for Parkinson\u2019s disease","volume":"4","author":"Mattammal","year":"1995","journal-title":"Neurodegeneration"},{"key":"10.1124\/jpet.119.262246_bib39","doi-asserted-by":"crossref","first-page":"31621","DOI":"10.1074\/jbc.M704737200","article-title":"Cellular oligomerization of \u03b1-synuclein is determined by the interaction of oxidized catechols with a C-terminal sequence","volume":"282","author":"Mazzulli","year":"2007","journal-title":"J Biol Chem"},{"key":"10.1124\/jpet.119.262246_bib40","doi-asserted-by":"crossref","first-page":"10068","DOI":"10.1523\/JNEUROSCI.0896-06.2006","article-title":"Cytosolic catechols inhibit \u03b1-synuclein aggregation and facilitate the formation of intracellular soluble oligomeric intermediates","volume":"26","author":"Mazzulli","year":"2006","journal-title":"J Neurosci"},{"key":"10.1124\/jpet.119.262246_bib41","doi-asserted-by":"crossref","first-page":"147251","DOI":"10.1155\/2014\/147251","article-title":"Copper and copper proteins in Parkinson\u2019s disease","volume":"2014","author":"Montes","year":"2014","journal-title":"Oxid Med Cell Longev"},{"key":"10.1124\/jpet.119.262246_bib42","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1002\/cpt.1548","article-title":"N-acetyl cysteine is associated with dopaminergic improvement in Parkinson\u2019s disease","volume":"106","author":"Monti","year":"2019","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/jpet.119.262246_bib43","doi-asserted-by":"crossref","first-page":"e0157602","DOI":"10.1371\/journal.pone.0157602","article-title":"N-Acetyl cysteine may support dopamine neurons in Parkinson\u2019s disease: preliminary clinical and cell line data","volume":"11","author":"Monti","year":"2016","journal-title":"PLoS One"},{"key":"10.1124\/jpet.119.262246_bib44","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1006\/exnr.1997.6662","article-title":"Neurotoxicity of endogenous cysteinylcatechols","volume":"148","author":"Montine","year":"1997","journal-title":"Exp Neurol"},{"key":"10.1124\/jpet.119.262246_bib45","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1002\/mds.27607","article-title":"The usual suspects, dopamine and alpha-synuclein, conspire to cause neurodegeneration","volume":"34","author":"Mor","year":"2019","journal-title":"Mov Disord"},{"key":"10.1124\/jpet.119.262246_bib46","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1038\/nn.4641","article-title":"Dopamine induces soluble \u03b1-synuclein oligomers and nigrostriatal degeneration","volume":"20","author":"Mor","year":"2017","journal-title":"Nat Neurosci"},{"key":"10.1124\/jpet.119.262246_bib47","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1093\/toxsci\/kfv016","article-title":"DT-diaphorase prevents aminochrome-induced alpha-synuclein oligomer formation and neurotoxicity","volume":"145","author":"Mu\u00f1oz","year":"2015","journal-title":"Toxicol Sci"},{"key":"10.1124\/jpet.119.262246_bib48","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0168-0102(97)00083-7","article-title":"Isoquinoline neurotoxins in the brain and Parkinson\u2019s disease","volume":"29","author":"Nagatsu","year":"1997","journal-title":"Neurosci Res"},{"key":"10.1124\/jpet.119.262246_bib49","doi-asserted-by":"crossref","first-page":"e15251","DOI":"10.1371\/journal.pone.0015251","article-title":"The neurotoxicity of DOPAL: behavioral and stereological evidence for its role in Parkinson disease pathogenesis","volume":"5","author":"Panneton","year":"2010","journal-title":"PLoS One"},{"key":"10.1124\/jpet.119.262246_bib50","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s12640-009-9059-4","article-title":"Molecular and neurochemical mechanisms in PD pathogenesis","volume":"16","author":"Paris","year":"2009","journal-title":"Neurotox Res"},{"key":"10.1124\/jpet.119.262246_bib51","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/j.jmb.2009.02.007","article-title":"Dopamine and the dopamine oxidation product 5,6-dihydroxylindole promote distinct on-pathway and off-pathway aggregation of \u03b1-synuclein in a pH-dependent manner","volume":"387","author":"Pham","year":"2009","journal-title":"J Mol Biol"},{"key":"10.1124\/jpet.119.262246_bib52","doi-asserted-by":"crossref","first-page":"40699","DOI":"10.1038\/srep40699","article-title":"DOPAL derived alpha-synuclein oligomers impair synaptic vesicles physiological function","volume":"7","author":"Plotegher","year":"2017","journal-title":"Sci Rep"},{"key":"10.1124\/jpet.119.262246_bib53","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1007\/s12031-013-0154-x","article-title":"Oxidative stress promotes uptake, accumulation, and oligomerization of extracellular \u03b1-synuclein in oligodendrocytes","volume":"52","author":"Pukass","year":"2014","journal-title":"J Mol Neurosci"},{"key":"10.1124\/jpet.119.262246_bib54","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1021\/tx9000557","article-title":"Protein reactivity of 3,4-dihydroxyphenylacetaldehyde, a toxic dopamine metabolite, is dependent on both the aldehyde and the catechol","volume":"22","author":"Rees","year":"2009","journal-title":"Chem Res Toxicol"},{"key":"10.1124\/jpet.119.262246_bib55","doi-asserted-by":"crossref","first-page":"14213","DOI":"10.1021\/acsomega.8b00993","article-title":"Tuning the balance between fibrillation and oligomerization of \u03b1-synuclein in the presence of dopamine","volume":"3","author":"Saha","year":"2018","journal-title":"ACS Omega"},{"key":"10.1124\/jpet.119.262246_bib56","doi-asserted-by":"crossref","first-page":"897","DOI":"10.4103\/1673-5374.208560","article-title":"On the role of endogenous neurotoxins and neuroprotection in Parkinson\u2019s disease","volume":"12","author":"Segura-Aguilar","year":"2017","journal-title":"Neural Regen Res"},{"key":"10.1124\/jpet.119.262246_bib57","doi-asserted-by":"crossref","first-page":"271","DOI":"10.3389\/fnins.2019.00271","article-title":"On the role of aminochrome in mitochondrial dysfunction and endoplasmic reticulum stress in Parkinson\u2019s disease","volume":"13","author":"Segura-Aguilar","year":"2019","journal-title":"Front Neurosci"},{"key":"10.1124\/jpet.119.262246_bib58","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1038\/42166","article-title":"\u03b1-Synuclein in Lewy bodies","volume":"388","author":"Spillantini","year":"1997","journal-title":"Nature"},{"key":"10.1124\/jpet.119.262246_bib59","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1016\/S0006-2952(01)00922-4","article-title":"Selective dopaminergic neurotoxicity of isoquinoline derivatives related to Parkinson\u2019s disease: studies using heterologous expression systems of the dopamine transporter","volume":"63","author":"Storch","year":"2002","journal-title":"Biochem Pharmacol"},{"key":"10.1124\/jpet.119.262246_bib60","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1089\/ars.2010.3521","article-title":"The origins of oxidant stress in Parkinson\u2019s disease and therapeutic strategies","volume":"14","author":"Surmeier","year":"2011","journal-title":"Antioxid Redox Signal"},{"key":"10.1124\/jpet.119.262246_bib61","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1007\/s00210-002-0640-0","article-title":"Astroglial dopamine transport is mediated by norepinephrine transporter","volume":"366","author":"Takeda","year":"2002","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"10.1124\/jpet.119.262246_bib62","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1002\/ana.10814","article-title":"Brain dopamine-stimulated adenylyl cyclase activity in Parkinson\u2019s disease, multiple system atrophy, and progressive supranuclear palsy","volume":"55","author":"Tong","year":"2004","journal-title":"Ann Neurol"},{"key":"10.1124\/jpet.119.262246_bib63","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1002\/ana.410440324","article-title":"Glial cytoplasmic inclusions in white matter oligodendrocytes of multiple system atrophy brains contain insoluble \u03b1-synuclein","volume":"44","author":"Tu","year":"1998","journal-title":"Ann Neurol"},{"key":"10.1124\/jpet.119.262246_bib64","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/S0304-3940(98)00407-8","article-title":"\u03b1-Synuclein immunoreactivity in glial cytoplasmic inclusions in multiple system atrophy","volume":"249","author":"Wakabayashi","year":"1998","journal-title":"Neurosci Lett"},{"key":"10.1124\/jpet.119.262246_bib65","doi-asserted-by":"crossref","first-page":"7374","DOI":"10.1002\/anie.201600277","article-title":"Toxic dopamine metabolite DOPAL forms an unexpected dicatechol pyrrole adduct with lysines of \u03b1-synuclein","volume":"55","author":"Werner-Allen","year":"2016","journal-title":"Angew Chem Int Ed Engl"},{"key":"10.1124\/jpet.119.262246_bib66","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.bbrc.2017.04.050","article-title":"Superoxide is the critical driver of DOPAL autoxidation, lysyl adduct formation, and crosslinking of \u03b1-synuclein","volume":"487","author":"Werner-Allen","year":"2017","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1124\/jpet.119.262246_bib67","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1021\/acs.biochem.7b01164","article-title":"Isoindole linkages provide a pathway for DOPAL-mediated cross-linking of \u03b1-synuclein","volume":"57","author":"Werner-Allen","year":"2018","journal-title":"Biochemistry"},{"key":"10.1124\/jpet.119.262246_bib68","doi-asserted-by":"crossref","first-page":"4194","DOI":"10.1073\/pnas.1100976108","article-title":"In vivo demonstration that \u03b1-synuclein oligomers are toxic","volume":"108","author":"Winner","year":"2011","journal-title":"Proc Natl Acad Sci USA"}],"container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524269214?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524269214?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/jpet.119.262246","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T13:59:28Z","timestamp":1739973568000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022356524269214"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2]]},"references-count":68,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["S0022356524269214"],"URL":"https:\/\/doi.org\/10.1124\/jpet.119.262246","relation":{},"ISSN":["0022-3565"],"issn-type":[{"value":"0022-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2020,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"3,4-Dihydroxyphenylacetaldehyde Is More Efficient than Dopamine in Oligomerizing and Quinonizing \u03b1-Synuclein","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pharmacology and Experimental Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/jpet.119.262246","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"U.S. Government work not protected by U.S. copyright","name":"copyright","label":"Copyright"}]}}